Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

中国生物技术企业百济基因周一宣布，其癌症治疗药物Brukinsa（zanubrutinib）已获得科威特、巴林和卡塔尔当局的批准，用于治疗至少接受过一次治疗的成年套细胞淋巴瘤患者。

In November 2019, Brukinsa was approved by the US Food and Drug Administration to treat mantle cell lymphoma in adult patients, marking the first cancer treatment developed in China to be approved for the US market.

2019年11月，Brukinsa获得美国食品药品监督管理局批准，用于治疗成年患者的套细胞淋巴瘤，这标志着中国开发的第一种癌症治疗方法获准进入美国市场。

In November 2019, the drug received accelerated approval in the US to treat mantle cell lymphoma in adult patients.

The drug is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The drug received accelerated approval from thexa0US Food and Drug Administration as a treatment for mantle cell lymphoma in adult patients who have received at least one prior therapy inxa0November 2019.

The USFDA's accelerated approval for BeiGene's Brukinsa (zanubrutinib) capsules, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, received positive media coverage in China and elsewhere.

In November, Chinese biomedicine company BeiGene Ltd's cancer treatment Brukinsa (zanubrutinib) capsules gained Accelerated Approval by the FDA under a Breakthrough Therapy designation to treat Mantle Cell lymphoma.

EBay, based in San Jose, California, held the mantle of being the top online destination for sellers before Amazon's marketplace gained traction over a decade ago with the help of FBA.

China has assumed the mantle of the workshop of the world for many years now, driven by its sheer size, complete industrial system and cheap labor force.

The drug treats adult patients with mantle cell lymphoma.

The FDA announced on Friday Beijing time its Accelerated Approval of the drug for treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, based on the overall response rate or how many patients experience a complete or partial shrinkage of their tumors after treatment.

Mantle cell lymphoma, or MCL, is a rare, aggressive form of non-Hodgkin's lymphoma, a cancer originating from the white blood cell called "lymphoma".

The United States Food and Drug Administration announced on Thursday it would grant accelerated approval to Chinese biomedicine company BeiGene Ltd's Brukinsa (zanubrutinib) capsules, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Mantle cell lymphoma, or MCL, is a rare, aggressive form of non-Hodgkin's lymphoma, which is a cancer developing from lymphocytes, a type of white blood cell.

Young consumers in China are taking a growing interest in cheaper, more accessible alternatives to mined gemsIt sparkles and shines like a diamond from the Earth's mantle, but it's grown in a laboratory.